Company
Headquarters: Snailwell, United Kingdom
Employees: 196
CEO: Mr. Paul C. Swinney
£190.0 Million
GBP as of Jan. 1, 2025
US$238.5 Million
Company | Market Cap (USD) |
---|---|
Intuitive | $216.79 B |
EssilorLuxottica SA | $116.96 B |
Becton, Dickinson and Company | $69.74 B |
HOYA Corp | $45.26 B |
Alcon Inc. | $41.55 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand; contamination control products, which include cleanroom, laboratory, pharmaceutical, cosmetic, and toiletry disinfectants under the Crystel brand; and airborne and veterinary device disinfectants under the Anistel brand. The company was founded in 1993 and is headquartered in Snailwell, the United Kingdom.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | June 30, 2023 |
Revenue TTM | £39.5 M |
EBITDA | £7.9 M |
Gross Profit TTM | £29.2 M |
Profit Margin | 15.29% |
Operating Margin | 16.13% |
Quarterly Revenue Growth | 19.90% |
Tristel plc has the following listings and related stock indices.
Stock: LSE: TSTL wb_incandescent
Stock: FSX: R1V wb_incandescent